design: use of lapatinib in adjuvant setting1
|Design 1 of this
randomised, multicentre, Phase III study will compare the efficacy of
lapatinib alone, versus trastuzumab alone, versus trastuzumab followed by
lapatinib, or versus lapatinib plus trastuzumab, as adjuvant treatment.
Design 2 is similar except that all patients will also receive concurrent
paclitaxel for the first 12 weeks after randomisation. This pioneering
collaborative group study is one of the largest adjuvant breast cancers
studies to date (planned enrolment of 8000 patients) and the first truly
global collaborative study. ALTTO will also provide the most comprehensive
translational research to date, aimed towards identifying those patients most
likely to respond to lapatinib treatment.
|1. ALTTO (EGF106708)
study design outline